The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
B-Type Natriuretic Peptide Clinical Activation in Aortic Stenosis
Open accessAbstract
Objectives This study was conducted to define the association between serum B-type natriuretic peptide (BNP) activation and survival after the diagnosis of aortic stenosis (AS).Background In AS, the link between BNP levels and clinical outcome is in dispute. Failure to account for the normal shifting of BNP ranges with aging in men and women, not using hard endpoints (survival), and not enrolling large series of patients have contributed to the uncertainty.Methods A program of prospective measurement of BNP levels with Doppler echocardiographic AS assessment during the same episode of care was conducted. BNP ratio (measured BNP/maximal normal BNP value specific to age and sex) >1 defined BNP clinical activation.Results In 1,953 consecutive patients with at least moderate AS (aortic valve area 1.03 ± 0.26 cm(2); mean gradient 36 ± 19 mm Hg), median BNP level was 252 pg/ml (interquartile range: 98 to 592 pg/ml); BNP ratio 2.46 (interquartile range 1.03 to 5.66); ejection fraction (EF) 57% ± 15%, and symptoms present in 60% of patients. After adjustment for all survival determinants, BNP clinical activation (BNP ratio >1) independently predicted mortality after diagnosis (p < 0.0001; hazard ratio [HR]: 1.91; 95% CI: 1.55 to 2.35) and provided incremental power to the survival predictive model (p < 0.0001). Eight-year survival was 62 ± 3% with normal BNP levels, 44 ± 3% with BNP ratio of 1 to 2 (adjusted HR: 1.49; 95% CI: 1.17 to 1.90), 25 ± 4% with BNP ratio of 2 to 3 (adjusted HR: 2.12; 95% CI: 1.63 to 2.75), and 15 ± 2% with BNP ratio of ≥3 (adjusted HR: 2.43; 95% CI: 1.94 to 3.05). This strong link to survival was confirmed in asymptomatic patients with normal EF (adjusted HR: 2.35 [95% CI: 1.57 to 3.56] for BNP clinical activation and 2.10 [95% CI: 1.32 to 3.36] for BNP ratio of 1 to 2, 2.25 [95% CI: 1.31 to 3.87] for BNP ratio of 2 to 3, 3.93 [95% CI: 2.40 to 6.43] for BNP ratio of ≥3). Aortic valve replacement was associated with survival improved by a similarly high margin (p = 0.54) with BNP ratio of <2 (HR: 0.68; 95% CI: 0.52 to 0.89; p = 0.003) or BNP ratio of >2 (HR: 0.56; 95% CI: 0.47 to 0.66; p < 0.0001).Conclusions In this large series of patients with AS, BNP clinical activation was associated with excess long-term mortality incrementally and independently of all baseline characteristics. Higher mortality with higher BNP clinical activation, even in asymptomatic patients, emphasizes the importance of appropriate clinical interpretation of BNP levels in managing patients with AS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies showed that elevated levels of brain natriuretic peptide, cardiac troponin, and galectin-3 are correlated with all-cause mortality in individuals with CAVS.6,7,8,9,10”
From Aortic valve-specific genes dysregulated in calcific aortic valve stenosis as potential biomarkers and therapeutic targets (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A BNP ratio of >1 was found to be a powerful independent predictor of mortality in AS, even in patients with asymptomatic AS187.”
From Calcific aortic stenosis (2016) · cites this paper as [187]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176857 · Cited by 8,487
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
Leon, M. B., Smith, C. R., Mack, M., Miller, D. C., Moses, J. W., Svensson, L. G., Tuzcu, E. M., Webb, J. G., Fontana, G. P., Makkar, R. R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008232 · Cited by 7,205
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881
Self-citationGuidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
Iung, B. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00201-x · Cited by 3,530
Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice
Baumgartner, H., Hung, J., Bermejo, J., Chambers, J. B., Evangelista, A., Griffin, B. P., Iung, B., Otto, C. M., Pellikka, P. A., & Quiñones, M. A. (2009) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2008.11.029 · Cited by 2,131
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.021 · Cited by 1,702
Predictors of Outcome in Severe, Asymptomatic Aortic Stenosis
Rosenhek, R., Binder, T. M., Porenta, G., Lang, I. M., Christ, G., SCHEMPER, M., Maurer, G., & Baumgartner, H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430903 · Cited by 1,332
Cited by
Sorted by citations
2017 ESC/EACTS Guidelines for the management of valvular heart disease
Baumgartner, H., Falk, V., Bax, J. J., Bonis, M. D., Hamm, C. W., Holm, P. J., Iung, B., Lancellotti, P., Lansac, E., Muñoz, D. R., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx391 · Cited by 6,356
2021 ESC/EACTS Guidelines for the management of valvular heart disease
Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., De Bonis, M., De Paulis, R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab395 · Cited by 5,685
2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Cuartas, M. M., Abreu, A., Adamo, M., Marsan, N. A., Barili, F., Bonaros, N. E., Cosyns, B., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf194 · Cited by 1,364
Lindman, B. R., Clavel, M.-A., Mathieu, P., Iung, B., Lancellotti, P., Otto, C. M., & Pibarot, P. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.6 · Cited by 982
Self-citationStaging classification of aortic stenosis based on the extent of cardiac damage
Généreux, P., Pîbarot, P., Redfors, B., Mack, M. J., Makkar, R., Jaber, W. A., Svensson, L. G., Kapadia, S. R., Tuzcu, E. M., Thourani, V. H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx381 · Cited by 769
2017 ESC/EACTS Guidelines for the management of valvular heart disease
Falk, V., Baumgartner, H., Bax, J. J., Bonis, M. D., Hamm, C. W., Holm, P. J., Iung, B., Lancellotti, P., Lansac, E., Muñoz, D. R., et al. (2017) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx324 · Cited by 638
2021 ESC/EACTS Guidelines for the management of valvular heart disease
Beyersdorf, F., Vahanian, A. S., Milojevic, M., Praz, F., Baldus, S. E., Bauersachs, J. K., Capodanno, D., Conradi, L., Bonis, M. D., Paulis, R. D., et al. (2021) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezab389 · Cited by 653
2021 ESC/EACTS Guidelines for the management of valvular heart disease
Vahanian, A. S., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S. E., Bauersachs, J. K., Capodanno, D., Conradi, L., Bonis, M. D., Paulis, R. D., et al. (2022) · EuroIntervention · doi:10.4244/eij-e-21-00009 · Cited by 393
JCS/JSCS/JATS/JSVS 2020 Guidelines on the Management of Valvular Heart Disease
Izumi, C., Eishi, K., Ashihara, K., Arita, T., Otsuji, Y., Kunihara, T., Komiya, T., Shibata, T., Seo, Y., Daimon, M., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0135 · Cited by 373
Généreux, P., Stone, G. W., O’Gara, P. T., Marquis‐Gravel, G., Redfors, B., Giustino, G., Pîbarot, P., Bax, J. J., Bonow, R. O., & Leon, M. B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.057 · Cited by 299
The Task Force for the management of COVID-19 of the European Society of Cardiology, Baigent, C., Windecker, S., Andreini, D., Arbelo, E., Barbato, E., Bartorelli, A. L., Baumbach, A., Behr, E. R., Berti, S. L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab697 · Cited by 177
Sex Dimorphism in the Myocardial Response to Aortic Stenosis
Treibel, T. A., Kozor, R., Fontana, M., Torlasco, C., Réant, P., Badiani, S., Espinoza, M., Yap, J. A., Dı́ez, J., Hughes, A. D., et al. (2017) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2017.08.025 · Cited by 131
Timing of intervention in aortic stenosis: a review of current and future strategies
Everett, R. J., Clavel, M.-A. A., Pîbarot, P., & Dweck, M. R. (2018) · Heart · doi:10.1136/heartjnl-2017-312304 · Cited by 127
Self-citationManagement strategies and future challenges for aortic valve disease
Bonow, R. O., Leon, M. B., Doshi, D., & Moat, N. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00586-9 · Cited by 107
Management of Asymptomatic Severe Aortic Stenosis
Lindman, B. R., Dweck, M. R., Lancellotti, P., Généreux, P., Piérard, L., O’Gara, P. T., & Bonow, R. O. (2019) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2019.01.036 · Cited by 108
Ramchand, J., Patel, S. K., Kearney, L. G., Matalanis, G. S., Farouque, O., Srivastava, P., & Burrell, L. M. (2019) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2019.09.005 · Cited by 105
ESC/EACTS vs. ACC/AHA guidelines for the management of severe aortic stenosis
Lee, G. S., Chikwe, J., Milojevic, M., Wijeysundera, H. C., Biondi‐Zoccai, G., Flather, M. D., Gaudino, M. F. L., Fremes, S. E., & Tam, D. Y. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac803 · Cited by 109
Echocardiographic predictors of outcomes in adults with aortic stenosis
Capoulade, R., Ven, F. L., Clavel, M.-A. A., Dumesnil, J. G., Dahou, A., Thébault, C., Arsenault, M., O’Connor, K., Bédard, É., Beaudoin, J., et al. (2016) · Heart · doi:10.1136/heartjnl-2015-308742 · Cited by 98
Self-citationBiomarkers of Calcific Aortic Valve Disease
Small, A., Kiss, D., Giri, J. S., Anwaruddin, S., Siddiqi, H. K., Guerraty, M. A., Chirinos, J. A., Ferrari, G. M., & Rader, D. J. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308615 · Cited by 98
The Role of Biomarkers in Valvular Heart Disease: Focus on Natriuretic Peptides
Bergler-Klein, J. K., Gyöngyösi, M., & Maurer, G. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.07.014 · Cited by 82
2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Cuartas, M. M., Abreu, A., Adamo, M., Marsan, N. A., Barili, F., Bonaros, N. E., Cosyns, B., et al. (2025) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaf276 · Cited by 97
Transcatheter heart valve interventions: where are we? Where are we going?
Prendergast, B., Baumgartner, H., Delgado, V., Gérard, O., Haude, M., Himmelmänn, A., Iung, B., Leafstedt, M., Lennartz, J., Maisano, F., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy668 · Cited by 75
B-type natriuretic peptide in patients with asymptomatic severe aortic stenosis
Nakatsuma, K., Taniguchi, T., Morimoto, T., Shiomi, H., Ando, K., Kanamori, N., Murata, K., Kitai, T., Kawase, Y., Izumi, C., et al. (2018) · Heart · doi:10.1136/heartjnl-2018-313746 · Cited by 64
Multimodality Imaging Strategies for the Assessment of Aortic Stenosis
Dulgheru, R., Pîbarot, P., Sengupta, P. P., Piérard, L., Rosenhek, R., Magné, J., Donal, E., Bernard, A., Fattouch, K., Cosyns, B., et al. (2016) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.115.004352 · Cited by 69
“(ratio-measured brain natriuretic peptide/normal reference brain natriuretic peptide for age and sex, >2).(55) CMR is not”
BackgroundZhang, B., Xu, H., Zhang, H., Liu, Q., Ye, Y., Hao, J., Zhao, Q., Qi, X., Liu, S., Zhang, E., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.031 · Cited by 63
Self-citationB-Type Natriuretic Peptides and Cardiac Troponins for Diagnosis and Risk-Stratification of Syncope
de Lavallaz, J. D. F., Badertscher, P., Nestelberger, T., Zimmermann, T., Miró, Ò., Salgado, E., Christ, M., Geigy, N., Cullen, L., Than, M. P., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038358 · Cited by 60
Timing of intervention in asymptomatic patients with valvular heart disease
Baumgartner, H., Iung, B., & Otto, C. M. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa485 · Cited by 57
“19 23”
Clavel, M.-A. A., Tribouilloy, C. M., Vanoverschelde, J., Pizarro, R., Suri, R. M., Szymanski, C., Lazam, S., OBERTI, P. F., Michelena, H. I., Jaffe, A. S., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.047 · Cited by 55
Self-citationThe Task Force for the management of COVID-19 of the European Society of Cardiology, Baigent, C., Windecker, S., Andreini, D., Arbelo, E., Barbato, E., Bartorelli, A. L., Baumbach, A., Behr, E. R., Berti, S. L., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab343 · Cited by 53
Elevated Plasma Soluble ST2 Is Associated with Heart Failure Symptoms and Outcome in Aortic Stenosis
Lancellotti, P., Dulgheru, R., Magné, J., Henri, C., Servais, L., Bouznad, N., Ancion, A., Martinez, C., Davin, L., Goff, C. M. L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138940 · Cited by 50
“Although adjusted for age and sex, BNP ratio [20, 21] did not improve the predictive accuracy of BNP.”
BackgroundMethodO'Neill, B. P., Guerrero, M. E., Thourani, V. H., Kodali, S., Heldman, A. W., Williams, M. R., Xu, K., Pichard, A. D., Mack, M. J., Babaliaros, V. C., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.01.561 · Cited by 49
Gu, H., Saeed, S., Boguslavskyi, A., Carr‐White, G., Chambers, J. B., & Chowienczyk, P. (2018) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2018.08.037 · Cited by 48
“predict events in asymptomatic AS (25,26) but may lack specificity.”
BackgroundNatriuretic Peptides for Risk Stratification of Patients With Valvular Aortic Stenosis
Parikh, V. Y., Kim, C., Siegel, R. J., Arsanjani, R., & Rader, F. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.001649 · Cited by 46
“As established in a large population sample,(7) BNP levels increase with aging, which is why some studies use a BNP ratio (ie, BNP levels adjusted for age-specific normal values).(8) The purpose of this review is to present the data that have emerged during the past 10 years about the usefulness of natriuretic peptide…”
MethodMoura, B., Aimo, A., Al‐Mohammad, A., Flammer, A. J., Barberis, V. I., Bayés‐Genís, A., Rocca, H. B., Fontes‐Carvalho, R., Grapsa, J., Hülsmann, M., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2339 · Cited by 44
Mizutani, K., Hara, M., Iwata, S., Murakami, T., Shibata, T., Yoshiyama, M., Naganuma, T., Yamanaka, F., Higashimori, A., Tada, N., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006112 · Cited by 43
Goublaire, C., Melissopoulou, M., Lobo, D., Kubota, N., Verdonk, C. G., Cimadevilla, C., Codogno, I., Brochet, É., Vahanian, A. S., & Messika–Zeitoun, D. (2017) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2017.03.020 · Cited by 43
Guía ESC/EACTS 2021 sobre el diagnóstico y tratamiento de las valvulopatías
Vahanian, A. S., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S. E., Bauersachs, J. K., Capodanno, D., Conradi, L., Bonis, M. D., Paulis, R. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.023 · Cited by 45
Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis
Vidula, M. K., Orlenko, A., Zhao, L., Salvador, L., Small, A. M., Horton, E., Cohen, J. B., Adusumalli, S., Denduluri, S., Kobayashi, T., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2361 · Cited by 38
Chen, S., Redfors, B., O'Neill, B. P., Clavel, M.-A. A., Pîbarot, P., Elmariah, S., Nazif, T. M., Crowley, A., Ben‐Yehuda, O., Finn, M. T., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz892 · Cited by 38
Self-citationAbramowitz, Y., Chakravarty, T., Jilaihawi, H., Lee, C., Cox, J. M., Sharma, R. P., Mangat, G., Cheng, W., & Makkar, R. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.09.031 · Cited by 36
“4%) 0 Postprocedural aortic valve gradient (mmHG) 5 (1-9) 5 (2-9) 4.”
Dahou, A., Clavel, M.-A., Capoulade, R., O’Connor, K., Ribeiro, H. B., Côté, N., Le Ven, F., Rodés-Cabau, J., Dumesnil, J. G., Mathieu, P., et al. (2018) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2017.06.018 · Cited by 37
Self-citationLindman, B. R., Clavel, M.-A. A., Abu-Alhayja’a, R., Côté, N., Dagenais, F., Novak, E. L., Voisine, P., Poulin, A., Arsenault, B. J., Desmeules, P., et al. (2018) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2018.07.039 · Cited by 34
Self-citationDixon, S. B., Howell, C. R., Lu, L., Plana, J. C., Joshi, V. M., Luepker, R. V., Durand, J., Ky, B., Lenihan, D. J., Jefferies, J. L., et al. (2020) · Cancer · doi:10.1002/cncr.33292 · Cited by 34
Henri, C., Dulgheru, R., Magné, J., Caballero, L., Laaraibi, S., Davin, L., Kou, S., Voilliot, D., Nchimi, A., Oury, C., et al. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.06.007 · Cited by 34
Ito, S., Miranda, W. R., Jaffe, A. S., & Oh, J. K. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.02.004 · Cited by 34
Self-citationGoodman, A., Kusunose, K., Popović, Z., Parikh, R., Barr, T., Sabik, J. F., Rodriguez, L. L., Svensson, L. G., Griffin, B. P., & Desai, M. Y. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002561 · Cited by 33
“DOI: 10.1161/JAHA.115.002561 Journal of the American Heart Association 9 BNP and Strain in Aortic Stenosis Goodman et al O R IG IN A L R E S E A R C H A previous report has suggested the use of different thresholds, based on age and sex.31 A recent report utilized BNP ratios generated based on these thresholds and dem…”
MethodInfluentialO’Leary, J., Clavel, M.-A. A., Chen, S., Goel, K., O'Neill, B. P., Elmariah, S., Crowley, A., Alu, M. C., Thourani, V. H., Leon, M. B., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.2614 · Cited by 32
Self-citationBiomarkers in Aortic Stenosis: A Systematic Review
Redfors, B., Furer, A., Lindman, B. R., Burkhoff, D., Marquis‐Gravel, G., Francese, D. P., Ben‐Yehuda, O., Pîbarot, P., Gillam, L. D., Leon, M. B., et al. (2017) · Structural Heart · doi:10.1080/24748706.2017.1329959 · Cited by 30
“A recent study showed that BNP activation, defined as the ratio between the measured BNP and the maximum expected BNP for a subject’s age and sex, was a strong and persistent predictor of mortality.(55) The predictive value of BNP may be lower in the elderly, the patient group most commonly affected by AS.”
BackgroundModels and Techniques to Study Aortic Valve Calcification in Vitro, ex Vivo and in Vivo. An Overview
Bogdanova, M., Zabirnyk, A., Malashicheva, A., Semenova, D., Kvitting, J. E., Kaljusto, M., Perez, M. D. M., Kostareva, A. A., Stensløkken, K., Sullivan, G. J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835825 · Cited by 35
Toutouzas, K. P., Stathogiannis, K. E., Latsios, G., Synetos, A. G., Drakopoulou, M. I., Penesopoulou, V., Michelongona, A., Tsiamis, E. G., & Tousoulis, D. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170727110241 · Cited by 28
Stähli, B. E., Gebhard, C., Saleh, L., Falk, V., Landmesser, U., Nietlispach, F., Maisano, F., Lüscher, T. F., Maier, W., & Binder, R. K. (2014) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.25788 · Cited by 27
Role of advanced left ventricular imaging in adults with aortic stenosis
Călin, A., Mateescu, A. D., Popescu, A. C., Bing, R., Dweck, M. R., & Popescu, B. A. (2020) · Heart · doi:10.1136/heartjnl-2019-315211 · Cited by 28
Catheter-Based Interventions for the Management of Valvular Heart Disease During Pregnancy
Elkayam, U., Bansal, P., & Mehra, A. (2022) · JACC Advances · doi:10.1016/j.jacadv.2022.100022 · Cited by 26
The ‘wait for symptoms’ strategy in asymptomatic severe aortic stenosis
Román, J. A. S., Vilacosta, I., Antunes, M. J., Iung, B., López, J., & Schäfers, H. (2020) · Heart · doi:10.1136/heartjnl-2020-317323 · Cited by 28
Timing of Intervention in Asymptomatic Patients with Aortic Stenosis
Sevilla, T., Revilla, A., & Román, J. A. S. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.11 · Cited by 21
Ratio of Acceleration Time to Ejection Time for Assessing Aortic Stenosis Severity
Chulián, S. G., Freire, S. J. C., Toro, R., Valpuesta, A. G., Mazuecos, J. B., & Vargas‐Machuca, J. C. (2015) · Echocardiography · doi:10.1111/echo.12978 · Cited by 24
“Several studies have demonstrated that plasma levels of natriuretic peptides are related to symptomatic status,(32) disease severity, and prognosis.(35,36) In our study, patients with AT/ET >0.”
BackgroundLindman, B. R., Pîbarot, P., Schwartz, A. J., Oldemeyer, J. B., Su, Y. R., Goel, K., Cohen, D. J., Fearon, W. F., Babaliaros, V. C., Daniels, D. V., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.074425 · Cited by 24
“6–10 These studies provide the rationale for the guideline recommendation that AVR is reasonable in patients with asymptomatic severe AS and elevated BNP (brain natriuretic peptide) to unload the heart to potentially prevent irreversible cardiac damage and its consequences.”
Duello, K. M., Nagel, J. P., Thomas, C. S., Blackshear, J. L., & Freeman, W. D. (2015) · Neurocritical Care · doi:10.1007/s12028-014-0105-6 · Cited by 23
The left ventricle in aortic stenosis – imaging assessment and clinical implications
Călin, A., Roşca, M., Beladan, C. C., Enache, R., Mateescu, A. D., Ginghină, C., & Popescu, B. A. (2015) · Cardiovascular Ultrasound · doi:10.1186/s12947-015-0017-4 · Cited by 24
“A serum BNP level higher than the normal upper limit for each individual patient (defined as BNP clinical activation) was a powerful predictor of long-term mortality, incrementally and independently of all baseline characteristics in a large cohort of patients with moderate and severe AS [74].”
BackgroundSeoudy, H., Frank, J., Neu, M., Güßefeld, N., Klaus, Y., Freitag‐Wolf, S., Lambers, M., Lutter, G., Dempfle, A., Rangrez, A. Y., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010876 · Cited by 23
“25 BNP is recognized in the current European Society of Cardiology and European Association for Cardio-Thoracic Surgery guidelines for the management of valvular heart disease 2 as the only biomarker with prognostic value in AS.”
Onishi, H., Naganuma, T., Izumo, M., Ouchi, T., Yuki, H., Mitomo, S., & Nakamura, S. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13946 · Cited by 20
Pathophysiology, emerging techniques for the assessment and novel treatment of aortic stenosis
Shah, S. M., Shah, J., Lakey, S., Garg, P., & Ripley, D. P. (2023) · Open Heart · doi:10.1136/openhrt-2022-002244 · Cited by 32
Blackshear, J. L., Kusumoto, H., Safford, R. E., Wysokinska, E. M., Thomas, C. S., Waldo, O. A., Stark, M. E., Shapiro, B. P., Ung, S., Moussa, I. D., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.11.016 · Cited by 22
Targeting vasoactive peptides for managing calcific aortic valve disease
Peltonen, T. O., Ohukainen, P., Ruskoaho, H. J., & Rysä, J. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1231933 · Cited by 21
“In a recent study, BNP clinical activation was detected as a predictor of long-term mortality in patients with moderate or severe AS (92), whereas in a large prospective cohort NT-proBNP had a poor diagnostic value for severe symptomatic AS in elderly patients (91).”
BackgroundTranscatheter Aortic Valve Replacement for Patients with Heart Failure
Himbert, D., & Vahanian, A. S. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2014.12.003 · Cited by 21
Kumar, A., Majmundar, M. M., Doshi, R. P., Kansara, T. M., Shariff, M., Shah, P., Adalja, D., Gullapalli, N., Vallabhajosyula, S., Panaich, S., et al. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.10.013 · Cited by 20
Aortic Valve Disease, Transcatheter Aortic Valve Replacement, and the Heart Failure Patient
Okumus, N. K., Abraham, S., Puri, R., & Tang, W. H. W. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.07.003 · Cited by 20
The role of cardiac biochemical markers in aortic stenosis
Chin, C., Djohan, A. H., & Lang, C. C. (2016) · Biomarkers · doi:10.3109/1354750x.2016.1141993 · Cited by 22
“association between BNP/NT-proBNP and adverse cardiovascular outcomes (Clavel et al., 2014; Lancellotti et al., 2010b; Monin et al., 2009) others have questioned their prognostic value (Ben-Dor et al.”
BackgroundInfluentialMaeder, M. T., Weber, L., Ammann, P., Buser, M., Ehl, N. F., Gerhard, M., Brenner, R., Haager, P. K., Maisano, F., & Rickli, H. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12614 · Cited by 20
Serum biomarkers in valvular heart disease
Gardezi, S. K. M., Coffey, S., Prendergast, B., & Myerson, S. G. (2017) · Heart · doi:10.1136/heartjnl-2016-310482 · Cited by 20
Cavalcante, P. N., Kanhouche, G., Rosa, V. E. E., Campos, C. M., Lopes, M. P., Lopes, M. A. A. A. D. M., Sampaio, R. O., Júnior, F. S. D. B., Tarasoutchi, F., & Abizaid, A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1182530 · Cited by 19
Auensen, A., Hussain, A. I., Falk, R. S., Walle‐Hansen, M. M., Bye, J., Pettersen, K. I., Aukrust, P., Ueland, T., & Gullestad, L. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179304 · Cited by 19
Blood, tissue and imaging biomarkers in calcific aortic valve stenosis
Shen, M., Tastet, L. L., Bergler-Klein, J. K., Pîbarot, P., & Clavel, M.-A. A. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000487 · Cited by 18
Self-citationGillam, L. D., Marcoff, L., & Shames, S. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.06.019 · Cited by 18
Vale, N. C., Teles, R. C., Madeira, S., Brito, J., Almeida, M., Nolasco, T., Abecasis, J., Rodrigues, G., Carmo, J., Furstenau, M. D. C., et al. (2018) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2017.06.016 · Cited by 18
“Patients with severe aortic valve stenosis have elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, due to increased myocardial wall stress and pressure overload.(3) Increased concentrations of this peptide have prognostic value in multiple heart conditions, and can be used for risk stratification.”
BackgroundPedersen, A. L. D., Povlsen, J. A., Dybro, A. M., Clemmensen, T. S., Larsen, A. H., Ladefoged, B. T., & Poulsen, S. H. (2020) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2020.07.013 · Cited by 17
Nguyen, V., Cimadevilla, C., Arangalage, D., Dehoux, M., Codogno, I., Duval, X., Tubiana, S., Vahanian, A. S., & Messika–Zeitoun, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.12.100 · Cited by 16
Blood biomarkers in left-sided valvular heart disease
Coisne, A., Lancellotti, P., Côté, N., Ternacle, J., Hecht, S., Grapsa, J., Hahn, R. T., Clavel, M.-A. A., Vannan, M. A., Lindman, B. R., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf232 · Cited by 15
Self-citationBiomarkers Associated with Mortality in Aortic Stenosis: A Systematic Review and Meta-Analysis
White, M., Baral, R., Ryding, A., Tsampasian, V., Ravindrarajah, T., Garg, P., Koskinas, K. C., Clark, A., & Vassiliou, V. S. (2021) · Medical Sciences · doi:10.3390/medsci9020029 · Cited by 26
Unique Aspects of Women's Valvular Heart Diseases: Impact for Diagnosis and Treatment
Powers, A., Lavoie, N., Nezet, E. L., & Clavel, M.-A. A. (2023) · CJC Open · doi:10.1016/j.cjco.2023.10.017 · Cited by 14
“26 Serial BNP assessments (every 6 or 12 months) can also be very useful, as they avoid the limitation of mandatory use of the expected value, by using patient ’ s baseline values as a control.”
MethodSelf-citationHadziselimovic, E., Greve, A. M., Sajadieh, A., Olsen, M. H., Kesäniemi, Y. A., Nienaber, C. A., Ray, S. G., Rossebø, A. B., Willenheimer, R. B., Wachtell, K., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2021.5916 · Cited by 14
YKL-40 (Chitinase-3-Like Protein 1) Serum Levels in Aortic Stenosis
Arain, F., Abraityte, A., Bogdanova, M., Solberg, O. G., Michelsen, A. E., Lekva, T., Aakhus, S., Holm, S., Halvorsen, B., Finsen, A. V., et al. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.119.006643 · Cited by 13
Assessment of Cardiac Damage in Aortic Stenosis
Fukui, M., Généreux, P., & Cavalcante, J. L. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.09.001 · Cited by 13
Sato, K., Kumar, A., Krishnaswamy, A., Mick, S., Desai, M. Y., Griffin, B. P., Kapadia, S. R., & Popović, Z. (2018) · Clinical Cardiology · doi:10.1002/clc.23138 · Cited by 13
“severity, left ventricular (LV) remodeling, and prognosis in severe aortic stenosis (AS).(1,2) While studies have shown the prognostic util-”
BackgroundInfluentialBarbieri, F., Senoner, T., Adukauskaitė, A., Dobner, S., Holfeld, J., Semsroth, S., Lambert, T., Zweiker, D., Theurl, T., Rainer, P. P., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.09.014 · Cited by 13
Aortic stenosis in patients with kidney failure: Is there an advantage for a PD-first policy ?
Candellier, A., Hénaut, L., Morelle, J., Choukroun, G. J., Jadoul, M. Y., Brazier, M., & Goffin, E. J. (2020) · Peritoneal Dialysis International · doi:10.1177/0896860820941371 · Cited by 13
Altes, A., Thellier, N., Bohbot, Y., Ringlé, A., Verdun, S., Lévy, F., Castel, A., Delelis, F., Mailliet, A., Tribouilloy, C. M., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021873 · Cited by 13
Factors associated with the progression of aortic valve calcification in older adults
Leibowitz, D. W., Yoshida, Y., Jin, Z., Nakanishi, K., Mannina, C. M., Elkind, M. S. V., Rundek, T., Homma, S., Sacco, R. L., & Tullio, M. R. D. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.03.059 · Cited by 11
Lv, J., Zhang, B., Ye, Y., Li, Z., Wang, W., Zhao, Q., Liu, Q., Zhao, Z., Zhang, H., Wang, B., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02971-y · Cited by 12
Multi-biomarker mortality prediction in patients with aortic stenosis undergoing valve replacement.
Spampinato, R., Bochen, R., Sieg, F., Weiss, S., Kornej, J., Haunschild, J., vonAspern, K., Strotdrees, E., Noack, T., Lehmann, S., et al. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.02.019 · Cited by 14
Bonow, R. O. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.030 · Cited by 12
“This has stimulated interest in circulating biomarkers as more objective markers of disease progression (13,14), but definitive studies are lacking.”
BackgroundHolmgren, A., Ljungberg, J., Hultdin, J., Johansson, B. H., Bergdahl, I. A., Näslund, U., & Söderberg, S. (2020) · Open Heart · doi:10.1136/openhrt-2020-001325 · Cited by 11
Nader, J., Metzinger, L., Maitrias, P., Caus, T., & Meuth, V. M. (2020) · Non-coding RNA Research · doi:10.1016/j.ncrna.2020.02.005 · Cited by 11
Great debate: all patients with asymptomatic severe aortic stenosis need valve replacement
Iung, B., Piérard, L., Magné, J., Messika–Zeitoun, D., Pîbarot, P., & Baumgartner, H. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad355 · Cited by 12
The Role of Extravalvular Cardiac Damage Staging in Aortic Valve Disease Management
Tastet, L. L., Généreux, P., Bernard, J., & Pîbarot, P. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.01.020 · Cited by 13
Perry, A., Stein, E. J., Biersmith, M. A., Fearon, W. F., Elmariah, S., Kim, J. B., Clark, D. E., Patel, J. N., Gonzales, H. M., Baker, M., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026529 · Cited by 11
Severe aortic valve stenosis: Symptoms, biochemical markers, and global longitudinal strain
Zappulla, P., Bottaro, G., Deste, W., Famà, F., Agnello, F. G., Trovato, D., Indelicato, A., Barbanti, M., Sgroi, C., Monte, I. P., et al. (2020) · Journal of Cardiovascular Echography · doi:10.4103/jcecho.jcecho_13_20 · Cited by 10
“Different studies[11,24-28] have presented the relation between B-type natriuretic peptide and the amount of LV fibrosis and myocardial dysfunction.”
BackgroundWatchful waiting care or early intervention in asymptomatic severe aortic stenosis: Where we are
Ennezat, P. V., Malergue, M., Jemtel, T. H. L., & Abergel, É. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.07.002 · Cited by 10
Prognostic Value of Lung Ultrasound in Aortic Stenosis
Szabó, I. A., Gargani, L., Morvai-Illés, B., Polestyuk-Németh, N., Frigy, A., Varga, A., & Ágoston, G. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.838479 · Cited by 10
Multiple biomarker panel to screen for severe aortic stenosis: results from the CASABLANCA study
Elmariah, S., McCarthy, C. P., Ibrahim, N. E., Furman, D., Mukai, R., Magaret, C. A., Rhyne, R. F., Barnes, G., van Kimmenade, R. R. J., & Januzzi, J. L. (2018) · Open Heart · doi:10.1136/openhrt-2018-000916 · Cited by 10
Metadata
- Authors
- Clavel, M.-A., Malouf, J., Michelena, H. I., Suri, R. M., Jaffe, A. S., Mahoney, D. W., & Enriquez-Sarano, M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Enriquez-Sarano, Maurice
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 63
- Issue
- 19
- Pages
- 2016-2025
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W56250199
- Cited by
- 226
- References
- 48
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 10 · 2023: 20 · 2022: 19 · 2021: 16 · 2020: 29 · 2019: 19 · 2018: 17 · 2017: 24 · 2016: 17 · 2015: 15 · 2014: 5
- FWCI
- 13.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Corpus Université Laval (Université Laval) (submittedVersion)
- Funders
- Canadian Institute of Health Research
- Abbott Diagnostics
- Edwards Lifesciences
- St. Jude Medical
- Sorin Group
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Aortic Disease and Treatment Approaches
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- brain natriuretic peptide, aortic stenosis, mortality prediction, survival after diagnosis, asymptomatic aortic stenosis, ejection fraction, Doppler echocardiography, prognostic factors, heart failure risk stratification, heart failure hospitalization, heart failure mortality, heart failure readmission
- MeSH terms
- Aged, Aged, 80 and over, Aortic Valve Stenosis, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pilot Projects, Prospective Studies, Time Factors, Cohort Studies, Biomarkers, Survival Rate, Natriuretic Peptide, Brain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
